Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triestrogen is a bioidentical hormone replacement therapy (BHRT) formulation consisting of three naturally occurring estrogens: estriol (E3), estradiol (E2), and estrone (E1). It is typically prepared by compounding pharmacies in a specific ratio, most commonly 80% estriol, 10% estradiol, and 10% estrone, designed to mimic the physiological estrogen profile of premenopausal women. While primarily utilized to manage vasomotor symptoms and other complications of menopause, clinical research has also explored its use as part of a multi-component hormonorestorative therapy to treat steroidopenia-associated hypercholesterolemia. By restoring youthful levels of steroid hormones, triestrogen helps maintain cholesterol homeostasis and normalize lipid profiles. As a compounded product, it is not a single proprietary drug developed by a specific pharmaceutical company but is widely used in individualized hormone therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triestrogen.